Agents such as anti-ST2 antibodies (anti-ST2 Ab) and Etokimab— which inhibit IL-33 signaling, are currently under investigation for their potential to mitigate inflammation and fibrosis in individuals with AIP and IgG4-RD [39]. The gene discussed is IL33; the disease is autoimmune pancreatitis.